Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04769505
Other study ID # SPIROMIND 39
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date March 27, 2023

Study information

Verified date March 2024
Source Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to assess the feasibility of a brief digital mindfulness-based intervention for COPD patients and its effectiveness regarding the reduction of psychological distress as well as stress.


Description:

Background: Patients with chronic obstructive pulmonary disease (COPD) do not only suffer from somatic symptoms but also from symptoms of anxiety and depression (defined as psychological distress) as well as stress. As pharmacological interventions showed only limited effectiveness in targeting the latter, a need for additional treatment options emerges. In other chronic conditions, mindfulness-based interventions (MBIs) are effective in reducing symptoms of psychological distress and stress. Despite first promising results, research on MBIs in COPD patients is still scarce and mixed regarding their effects. Furthermore, it is crucial to implement mental health interventions adapted to the needs of COPD patients. Due to often experienced physical limitations and impaired mobility, digital MBIs seem particularly promising. Aim and Research Questions: Building on the above, this pilot randomized controlled trial aims to examine a) the feasibility of a brief digital MBI for COPD patients and b) its effects on psychological distress and stress. Methods: 30 psychologically distressed (assessed by the Hospital Anxiety and Depression Scale, HADS-A ≥ 8 or HADS-D ≥ 8) COPD patients are screened for inclusion and exclusion criteria in a telephone interview and randomly assigned to the MBI (plus treatment as usual) or waitlist control group (treatment as usual). After a single face-to-face introductory session, patients in the MBI condition are instructed to conduct at least one of four brief audio-guided mindfulness exercises (10-15min) daily for 8 weeks, delivered on their smartphones. Following an ecological momentary approach, psychological and respiratory variables (e.g. subjective stress, dyspnoea) are assessed before and after each exercise. These data will be analysed using multilevel modelling. Moreover, primary (psychological distress) and secondary outcomes (e.g. chronic stress, fatigue) are measured at baseline, 4 weeks, 8 weeks, and follow-up, including questionnaires and assessments of biological stress markers (hair cortisol, heart rate variability, electrodermal activity). The data will be analysed using repeated measures ANOVAs. Finally, in semi-structured telephone exit interviews with 15 patients of the MBI group, the intervention's feasibility will be explored using a thematic analysis approach.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 27, 2023
Est. primary completion date December 5, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion criteria: 1. spirometry confirmed (FEV1<80%) COPD diagnosis 2. psychological distress (as assessed by the Hospital Anxiety and Depression Scale): HADS-A = 8 OR HADS-D = 8 OR* 3. age = 40 years 4. ability to understand German 5. physical and mental capability to attend the intervention, judged by the treating physician 6. life expectancy > 6 months as judged by treating physician 7. ability to use a smartphone 8. ability not to smoke for the duration of the measurement time points (2-3 hours) (This criterion has been added later, because we learned that this was a problem for some participants. However, smoking during the measurements heavily affects biomarker data and the subjective stress response to a stress induction protocol.) Exclusion Criteria: 1. auditory impairment 2. active asthma diagnosis ("Regardless of your COPD, have you had allergies and asthma in childhood or adolescence and needed medication for them at that time?" If no: No active asthma. If yes: "Is your asthma active and a problem now in addition to your COPD and do you currently need asthma medications because of it?" If no: No active asthma. If yes: exclusion)** 3. any other known severe comorbidities such as heart failure (LVF<35%), uncontrolled diabetes, concomitant cancer, stroke, unstable coronary heart disease, respiratory failure 4. history of/current severe psychological disorder (e.g. schizophrenia, severe cognitive impairment) 5. current acute exacerbation of COPD 6. any other relevant acute health crisis interfering with the study intervention (e.g. Covid-19) 7. receiving any psychosocial treatment (e.g. psychotherapy) 8. regular other systematic mind-body-practice (*) When the only exclusion criterion was the HADS, which was often the case, we contacted the participants two months later to screen them again and included them, if they were eligible. (**) We further specified this criterion, as we learned that many patients were told to probably have asthma without them knowing exactly if they had an active asthma diagnosis.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
digital mindfulness-based intervention (MBI)
The digital MBI consists of four auditory guided mindfulness exercises lasting between 10 and 15 minutes. The four exercises are a body scan and three sitting meditations (awareness of the heartbeat, awareness of the body, awareness of sounds). The exercises can be conducted via a software (https://www.movisens.com/de/produkte/movisensxs/) on participants' smartphones. Participants will be familiarized with the concept of mindfulness and the intervention in a single face-to-face introductory session. Additionally, participants will receive a manual, containing all relevant information. Participants will be instructed to practice at least once daily over the course of eight weeks. We recommended to come up with a fixed time point for the mindfulness practice to facilitate a routine. They can choose individually between the exercises. After the intervention period, participants received the exercises as audio files and could continue practicing.

Locations

Country Name City State
Austria Klinik Ottakring Vienna

Sponsors (5)

Lead Sponsor Collaborator
Karl Landsteiner Institute for Lung Research and Pneumological Oncology Klinik Floridsdorf, Klinik Ottakring, Therme Wien Med (Ambulant Pulmonary Rehabilitation), University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Psychological distress Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement, interpreting both subscales for anxiety and depression baseline - 4 weeks
Primary Psychological distress Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement, interpreting both subscales for anxiety and depression baseline - 8 weeks
Primary Patient's experiences with the digital MBI patients' experiences assessed in the exit interview (qualitative and quantitative data) 8 weeks
Secondary Chronic stress assessed by Perceived Stress Scale (PSS-10; Cohen & Williamson, 1988; German version Klein et al., 2016), scores 0-40, lower scores indicate improvement baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Health related quality of life Chronic Respiratory Questionnaire (CRQ-SAS; German version Schünemann et al., 2003), scores: 20-140, higher scores indicate improvement baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Health status impairment COPD Assessment Test (CAT; Jones et al., 2009), scores 0-40, lower scores indicate improvement baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Fatigue Multidimensional Fatigue Inventory (MFI-20; German version Schwarz, Krauss, & Hinz, 2003), scores 0-80, items have different polarity baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Mindfulness Freiburger Mindfulness Inventory short form (FMI short form; Walach, Buchheld, Buttenmüller, Kleinknecht, & Schmidt, 2006), scores 0-42, higher scores indicate improvement baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Self-compassion Self-Compassion Scale short form (SCS short form; Raes, Pommier, Neff, & Van Gucht, 2011; German version Hupfeld & Ruffieux, 2011), scores 12-60, items have different polarity baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Breathlessness catastrophizing Breathlessness Catastrophizing Scale (BCS; Solomon et al., 2015; German version adapted analogue to Pain Catastrophizing Scale Meyer, Sprott, & Mannion, 2008), scores 0-52, lower scores indicate improvement baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Stress reactivity the reactivity to stress assessed via examining heart rate variability (RMSSD) during the exposure to a mental stressor (stroop test) baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Stress reactivity the reactivity to stress assessed via examining skin conductance level during the exposure to a mental stressor (stroop test) baseline, 4 weeks, 8 weeks, 4 months, 6 months
Secondary Hair cortisol concentration of hair cortisol (as biomarker for chronic stress) baseline, 8 weeks, 4 months, 6 months
Secondary Psychological distress Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement baseline, 4 months, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05008081 - The CATALINA Study
Completed NCT06118684 - Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin Phase 1
Recruiting NCT05808621 - Muscle Oxygenation in Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT05769738 - The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation Phase 3
Recruiting NCT04816695 - Volatolom Variation in Severe COPD During Hospitalization for Exacerbation and After Hospitalization (VOC-BPCO-Exa) N/A
Completed NCT05991778 - Bioelectrical Impedance in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients
Completed NCT05079009 - Effects of Blood Pulsatility on Von Willebrand Factor During ECCO2R N/A
Not yet recruiting NCT06105814 - Improved Diagnostics, Treatment and Follow-up of Acute Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Completed NCT05699720 - Acute Exacerbation of COPD and Nebulized Magnesium Sulphate N/A
Recruiting NCT04223050 - Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation Phase 4
Terminated NCT04828837 - Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects N/A
Completed NCT05776654 - Wearable Devices in the Recovery Phase of Acute Exacerbations of COPD (AECOPDs)
Completed NCT05691387 - Comparison of Active Cycle of Breathing Technique and Pursed Lip Breathing With TheraPep N/A